MedTrace Logo

Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

NCT01454687 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-04-11

No results posted yet for this study

Summary

The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

Conditions

  • Epidermolysis Bullosa

Interventions

PROCEDURE

Grafting of Autologous Cultured Revertant Keratinocytes

Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas

Sponsors & Collaborators

Principal Investigators

  • Alfred Lane, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454687 on ClinicalTrials.gov